(Press-News.org) London, UK, Saturday 12 April 2014: Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary composite endpoint of achieving a serum alkaline phosphatase (ALP) activity of less than 1.67 times the upper limit of normal (ULN), a total bilirubin within normal limits, and at least a 15% decrease in ALP.
The proportion of patients meeting the primary endpoint was: 47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group vs. only 10% in the placebo group (both dose groups p END
Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients
2014-04-12
ELSE PRESS RELEASES FROM THIS DATE:
Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients
2014-04-12
London, UK, Saturday 12 April 2014: Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
"Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of Ankara, Turkey.
In the first study , CHB patients ...
New Chinese herbal medicine has significant potential in treating hepatitis C
2014-04-12
London, UK, Saturday 12 April 2014: Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.[i]
SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. In Chinese medicine, it is used to treat sore throats and inflammations. The function of SBEL1 ...
Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients
2014-04-12
London, UK, Saturday 12 April 2014: Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014.
"With cure rates well in excess of 90% with as little as eight weeks of treatment for some patients, these data represent ...
Gut microbiota may play a role in the development of alcoholic liver disease
2014-04-12
London, UK, Saturday 12 April 2014: Exciting new data presented today at the International Liver Congress™ 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).1 Though an early stage animal model, the French study highlights the possibility of preventing ALD with faecal microbiota transplantation – the engrafting of new microbiota, usually through administering human faecal material from a healthy donor into the colon of a recipient.2
In the study, two groups of germ-free mice received gut microbiota transplants ...
Low vitamin D linked to fatty liver disease in UK children
2014-04-12
London, UK, Saturday 12 April 2014: A UK study[i] investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity.
The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analysed the medical records of 120 paediatric patients with NAFLD.
The findings could carry significant implications ...
New advances in HCC diagnosis, staging and treatment all predicted to improve patient outcomes
2014-04-12
London, UK, Saturday 12 April 2014: Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
"Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant Gastroenterologist at Newcastle Hospitals NHS Foundation Trust, ...
New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients
2014-04-12
London, UK, Saturday 12 April 2014: The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014.
The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333.
"Using this investigational ...
New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
2014-04-12
London, UK, Saturday 12 April 2014: Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients.
Overall, 65.4% of patients achieved SVR12 (82.9% of treatment-naïve, 86.4% ...
The Lancet Oncology: Challenges to effective cancer control in China, India, and Russia
2014-04-11
The Lancet Oncology today [Friday 11 April] publishes a major new Commission examining the challenges to effective cancer control in China, India, and Russia – which together experience 46% of all new cancers worldwide, and account for more than half (52%) of all cancer deaths globally. The Commission was led by Professor Paul Goss, of Harvard Medical School and Massachusetts General Hospital Cancer Center, USA, in collaboration with over 40 leading cancer experts from the regions studied, and across the world.
At the same time, the journal also publishes a three part ...
UAlberta researchers examine metabolism in defective cells
2014-04-11
UAlberta researchers are taking a closer look at how two metabolic pathways interact to increase the lifespan of cells with mitochondrial defects. Magnus Friis is the lead author of the study, which was published online on April 10 and will be published in the April 24 issue of Cell Reports.
Mitochondria produce energy for cells through oxidative metabolism, but the process produces toxic byproducts that can accumulate and cause defects in the cell's mitochondria. These defects, in turn, affect the cell's ability to generate energy and can potentially lead to cell death ...